

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
May 6, 2020
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, May 6, 2020.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Divya Ahuja, MD
Gregory Browning, MD
Thomas Phillips, RPh
Kimberly Rudd, MD

Edward Behling, MD
Duncan Norton, MD
Erika Tillery, PharmD

Joni Bolinger, MD
Cheryl Hartvigsen, RPh
Kenric Ware, PharmD

SC DHHS Staff:

Jim Bradford, MD
Bryan Amick, PharmD
William Wynn, PharmD
Byron Roberts, JD
Janet Giles

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, February 5, 2020

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Teva	Ryan Norman, PharmD, MBA	Austedo
Neurocrine	Yeni Quintana, MSN, DHSc, ARNP	Ingrezza
Ironshore	Charles R. Hatcher, III, MD	Jornay PM

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Class for Review

Movement Disorders

Classes for Re-Review

Acne Agents (Topical)

Attention Deficit Hyperactivity Disorder Agents

The chart below represents the recommendations from the P & T Committee:

MOVEMENT DISORDERS	
Preferred	Non-Preferred
Austedo	Ingrezza
Tetrabenazine	Xenazine
ACNE AGENTS (TOPICAL)	
Preferred	Non-Preferred
Azelex	Adapalene/benzoyl
Clindamycin/benzoyl peroxide‡	Differin/Plixda
Clindamycin phosphate (soln)	Benzaclin/Duac/Neuac/Onexton
Benzoyl peroxide 5 & 10% wash	Benzoyl peroxide/erythromycin
Benzoyl peroxide 6 & 9% cleanser	Benzoyl peroxide/hydrocortisone
Erythromycin soln/med swab	Benzoyl peroxide/salicylic
Retin-A cream/gel	Clindamycin phosphate ⁺
	Dapsone
	Duac
	Ery/Erygel
	Erythromycin gel ⁺
	Neuac
	Epiduo/Forte
	Fabior
	Sodium Sulfacetamide 10% wash ⁺
	Sodium Sulfacetamide/sulfur ⁺
	Tazaorac

ACNE AGENTS (TOPICAL) (continued)	
Preferred	Non-Preferred
	Tretinoin gen and brands Veltin/Ziana
ATTENTION DEFICIT HYPERACTIVITY DISORDER	
Preferred	Non-Preferred
Atomoxetine	Adenzyis ER/XR ODT
Adderall XR‡	Adhansia XR
Clonidine ER	Aptensio XR
Concerta‡	Amphetamine salts combo IR/XR ⁺
Dextroamphetamine tabs/caps	Methylphenidate ER ⁺
Dyanavel	Cotempla XR ODT
Guanfacine ER	Daytrana
Focalin IR‡/XR	Dexedrine
Methylphenidate CD	Evekeo/ODT
Methylphenidate IR/LA/SR	Dexmethylphenidate IR ⁺
Quillivant XR	Intuniv
Quillichew ER	Kapvay
Vyvanse tabs/caps	Lisdexamfetamine
	Methylin
	Methylphenidate ER
	Mydayis
	Procentra
	Ritalin/Ritalin LA
	Strattera
	Zenzedi

‡ Indicates “Added as Preferred”

+ Indicates “Moved to Non-Preferred”

5. Old Business

None

6. New Business

Lisa presented new drugs to market. Bryan provided an overview of COVID 19 initiatives including access to care, modifying Medicaid benefits/social distancing, maintaining access to services. SC DHHS has suspended annual eligibility redetermination process for those recipients currently covered and will create a limited benefit for uninsured recipients. Also, Bryan discussed expansion of visits for behavioral health, pediatric, PT, OT and substance use disorders with a nurse call triage phone line. SC DHHS has removed PA criteria for DME (oxygen therapy) and Skilled Nursing Facility admissions. Benefit limitations and cost share have been removed. COVID testing available at no cost. SC DHHS is also focusing on the (1) Community Engagement Waiver timeline, (2) response to the opioid epidemic (guidance issued), and (3) financial/budgetary impacts (↓funding/↑unemployed).

William and Byron did confirm virtual attendance satisfies the P&T Bylaws.

7. Resolved Items

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Class for Review

Movement Disorders¹

Classes for Re-Review

Acne Agents (Topical)

Attention Deficit Hyperactivity Disorder Agents

¹ SC DHHS reviewed the P&T Committee's concerns and will not place the Movement Disorders class on the PDL.

8. Closing Comments

The next meeting will be held on Wednesday, August 5, 2020.

9. Adjournment

The meeting adjourned at 5:30 p.m.